Emke Maréchal1,2, Karolien Beel3, Roel Crols4,5, Danielle Hernalsteen6, Barbara Willekens7,8. 1. Department of Neurology, ZNA Middelheim, Lindendreef 1, 2020, Antwerp, Belgium. emke.marechal@zna.be. 2. Department of Neurology, Antwerp University Hospital, Antwerp, Belgium. emke.marechal@zna.be. 3. Department of Hematology, ZNA Middelheim, Antwerp, Belgium. 4. Department of Neurology, ZNA Middelheim, Lindendreef 1, 2020, Antwerp, Belgium. 5. Department of Neurology, AZ Heilige Familie, Reet, Belgium. 6. Department of Radiology, ZNA Middelheim, Antwerp, Belgium. 7. Department of Neurology, Antwerp University Hospital, Antwerp, Belgium. 8. Translational Neurosciences and Laboratory for Experimental Hematology, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
Abstract
PURPOSE: To describe the development of progressive multifocal leukoencephalopathy (PML) in a patient with primary immune deficiency (PID) due to a NFKB1 (nuclear factor kB subunit 1) mutation, who was treated successfully with a combination of mirtazapine and mefloquine. METHODS: We've based the treatment of our patient on literature research and provide a review of PML in CVID patients. RESULTS: Only a few reports have been published on the occurrence of PML in PID. PML is mainly observed in patients with reduced cellular immunity, which was not the case in our patient. Successful treatment options in this population are limited. Though severely disabled, our patient still survives, more than 4 years after symptom onset and shows consistent improvement on MRI (magnetic resonance imaging) and CSF (cerebrospinal fluid) analysis. CONCLUSION: We conclude that some patients with PML might be treatable and can show long-term survival although neurological deficits remain. Involvement of humoral immunity in the pathogenesis of PML as well as the possible role of NFKB1 mutations in response to specific pathogens deserves further investigation.
PURPOSE: To describe the development of progressive multifocal leukoencephalopathy (PML) in a patient with primary immune deficiency (PID) due to a NFKB1 (nuclear factor kB subunit 1) mutation, who was treated successfully with a combination of mirtazapine and mefloquine. METHODS: We've based the treatment of our patient on literature research and provide a review of PML in CVIDpatients. RESULTS: Only a few reports have been published on the occurrence of PML in PID. PML is mainly observed in patients with reduced cellular immunity, which was not the case in our patient. Successful treatment options in this population are limited. Though severely disabled, our patient still survives, more than 4 years after symptom onset and shows consistent improvement on MRI (magnetic resonance imaging) and CSF (cerebrospinal fluid) analysis. CONCLUSION: We conclude that some patients with PML might be treatable and can show long-term survival although neurological deficits remain. Involvement of humoral immunity in the pathogenesis of PML as well as the possible role of NFKB1 mutations in response to specific pathogens deserves further investigation.
Authors: Rebekka Kurmann; Christian Weisstanner; Piotr Kardas; Hans H Hirsch; Roland Wiest; Bernhard Lämmle; Hansjakob Furrer; Renaud Du Pasquier; Claudio L Bassetti; Mathias Sturzenegger; Heinz Krestel Journal: J Neurovirol Date: 2015-04-28 Impact factor: 2.643
Authors: Shilpi Narula; David F LaRosa; Malek Kamoun; Josep Dalmau; Arnold I Levinson Journal: Ann Allergy Asthma Immunol Date: 2007-05 Impact factor: 6.347
Authors: Deniz Durali; Marie-Ghislaine de Goër de Herve; Jacques Gasnault; Yassine Taoufik Journal: Front Immunol Date: 2015-05-19 Impact factor: 7.561
Authors: Paul Tuijnenburg; Hana Lango Allen; Siobhan O Burns; Daniel Greene; Machiel H Jansen; Emily Staples; Jonathan Stephens; Keren J Carss; Daniele Biasci; Helen Baxendale; Moira Thomas; Anita Chandra; Sorena Kiani-Alikhan; Hilary J Longhurst; Suranjith L Seneviratne; Eric Oksenhendler; Ilenia Simeoni; Godelieve J de Bree; Anton T J Tool; Ester M M van Leeuwen; Eduard H T M Ebberink; Alexander B Meijer; Salih Tuna; Deborah Whitehorn; Matthew Brown; Ernest Turro; Adrian J Thrasher; Kenneth G C Smith; James E Thaventhiran; Taco W Kuijpers Journal: J Allergy Clin Immunol Date: 2018-03-02 Impact factor: 10.793